U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. AURA3: Lose control of bowel movements
  1. Section N/A

AURA3: Lose control of bowel movements

Project Patient Voice is intended to be used with a healthcare professional when discussing the potential symptoms related to a cancer and cancer treatment. Do not rely on Project Patient Voice alone to make decisions about medical care. Do not use Project Patient Voice to substitute for advice from your health care professional. Conclusions about patient experiences with symptoms may be limited because not all symptoms may have been captured by the patient-reported questionnaire.

← Back to summary table

Download symptom data (XLSX, 24KB)

In AURA3 Study, Patients Were Asked: "In the last 7 days, how OFTEN did you LOSE CONTROL OF BOWEL MOVEMENTS?"

Patients scored the frequency of their Loss of Control of Bowel Movements on a 5-point scale (Never, Rarely, Occasionally, Frequently, Almost Constantly)

Patient-Reported Loss of Control of Bowel Movements During the First 24 Weeks on Treatment for Patients Who Completed a Questionnaire:

Figure 1 shows the percentage of patients reporting how often they had Loss of Control of Bowel Movements at each time point. For example, at week 2, 6% of patients taking Tagrisso reported Loss of Control of Bowel Movements (ranging from Rarely to Frequently). The range of patients who had any Loss of Control of Bowel Movements during the first 24 weeks of treatment with Tagrisso was between 6% - 13%. Click here for more information on how to read the graphs below.

Figure 1. Patient-Reported Loss of Control of Bowel Movements During the First 24 Weeks on Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, showing proportion of patients reporting the frequency of Loss of Control of Bowel Movements at each time point through the first 24 weeks of treatment. For example, at week 2, 6% of patients taking Tagrisso reported Loss of Control of Bowel Movements (ranging from Rarely to Frequently).

All responses from patients' experiences just before and up to week 24 on-treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Loss of Control of Bowel Movements That Patients Reported During the First 24 Weeks on Treatment

Figure 2. Worst Patient-Reported Loss of Control of Bowel Movements During the First 24 Weeks on Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, summarizing the percentage of patients by worst reported Loss of Control of Bowel Movements during the first 24 weeks of the clinical trial. In the Tagrisso arm, Never (64%), Rarely (13%), Occasionally (15%), Frequently (4%) and Almost constantly (4%). In the chemotherapy arm, Never (58%), Rarely (25%), Occasionally (13%), Frequently (4%) and Almost constantly (0%).

Patients with at least one on-treatment Loss of Control of Bowel Movements score were included in the analysis. Tagrisso (N=99), Chemotherapy (N=55).

Some Patients Did Not Report Loss of Control of Bowel Movements Before Treatment:

For patients that did not report Loss of Control of Bowel Movements before treatment, Figure 3 shows the percentage of patients reporting how often they had Loss of Control of Bowel Movements between weeks 1 and 24.

Figure 3. Patient-Reported Loss of Control of Bowel Movements During the First 24 Weeks on Treatment: Patients Without Fecal Incontinence Before Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no Loss of Control of Bowel Movements before treatment. The bar charts show the proportion of patients reporting frequency of Loss of Control of Bowel Movements at each time point through 24 weeks. For example, at week 2, 4% of patients taking Tagrisso reported Loss of Control of Bowel Movements (ranging from Rarely to Frequently).

All responses from patients who did not report Loss of Control of Bowel Movements before treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Loss of Control of Bowel Movements That Patients Reported During the First 24 Weeks on Treatment, for Patients Who Did Not Have Loss of Control of Bowel Movements Before Treatment:

Figure 4. Worst Patient-Reported Loss of Control of Bowel Movements During the First 24 Weeks on Treatment: Patients Without Loss of Control of Bowel Movements Before Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no Loss of Control of Bowel Movements before treatment. The pie charts summarize the percentage of patients by worst reported Loss of Control of Bowel Movements. In the Tagrisso arm, Never (73%), Rarely (9%), Occasionally (11%), Frequently (5%) and Almost constantly (2%). In the chemotherapy arm, Never (63%), Rarely (26%), Occasionally (8%), Frequently (3%) and Almost constantly (0%).

Patients who had no Loss of Control of Bowel Movements before treatment and at least one on-treatment Fecal Incontinence score were included in the analysis. Tagrisso (N=75), Chemotherapy (N=38).

Back to Top